Literature DB >> 11015433

Failure to detect circulating Aspergillus markers in a patient with chronic granulomatous disease and invasive aspergillosis.

P E Verweij1, C M Weemaes, J H Curfs, S Bretagne, J F Meis.   

Abstract

We report a patient with chronic granulomatous disease who developed invasive pulmonary aspergillosis and a subphrenic abscess. During treatment, high levels of Aspergillus antigen were detected in the abscess, but circulating antigen and Aspergillus DNA were undetectable in the serum.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11015433      PMCID： PMC87506     

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  7 in total

1.  Comparison of serum galactomannan antigen detection and competitive polymerase chain reaction for diagnosing invasive aspergillosis.

Authors:  S Bretagne; J M Costa; E Bart-Delabesse; N Dhédin; C Rieux; C Cordonnier
Journal:  Clin Infect Dis       Date:  1998-06       Impact factor: 9.079

2.  Detection and identification of fungal pathogens in blood by using molecular probes.

Authors:  H Einsele; H Hebart; G Roller; J Löffler; I Rothenhofer; C A Müller; R A Bowden; J van Burik; D Engelhard; L Kanz; U Schumacher
Journal:  J Clin Microbiol       Date:  1997-06       Impact factor: 5.948

3.  A new sensitive sandwich enzyme-linked immunosorbent assay to detect galactofuran in patients with invasive aspergillosis.

Authors:  D Stynen; A Goris; J Sarfati; J P Latgé
Journal:  J Clin Microbiol       Date:  1995-02       Impact factor: 5.948

4.  Comparison of antigen detection and PCR assay using bronchoalveolar lavage fluid for diagnosing invasive pulmonary aspergillosis in patients receiving treatment for hematological malignancies.

Authors:  P E Verweij; J P Latgé; A J Rijs; W J Melchers; B E De Pauw; J A Hoogkamp-Korstanje; J F Meis
Journal:  J Clin Microbiol       Date:  1995-12       Impact factor: 5.948

5.  Autopsy-controlled prospective evaluation of serial screening for circulating galactomannan by a sandwich enzyme-linked immunosorbent assay for hematological patients at risk for invasive Aspergillosis.

Authors:  J Maertens; J Verhaegen; H Demuynck; P Brock; G Verhoef; P Vandenberghe; J Van Eldere; L Verbist; M Boogaerts
Journal:  J Clin Microbiol       Date:  1999-10       Impact factor: 5.948

6.  Detection of Aspergillus species DNA in bronchoalveolar lavage samples by competitive PCR.

Authors:  S Bretagne; J M Costa; A Marmorat-Khuong; F Poron; C Cordonnier; M Vidaud; J Fleury-Feith
Journal:  J Clin Microbiol       Date:  1995-05       Impact factor: 5.948

7.  Prospective sandwich enzyme-linked immunosorbent assay for serum galactomannan: early predictive value and clinical use in invasive aspergillosis.

Authors:  P Rohrlich; J Sarfati; P Mariani; M Duval; A Carol; C Saint-Martin; E Bingen; J P Latge; E Vilmer
Journal:  Pediatr Infect Dis J       Date:  1996-03       Impact factor: 2.129
  7 in total
  13 in total

1.  The Role of Biomarkers for Diagnosis of and Therapeutic Decisions Related to Invasive Aspergillosis in Children.

Authors:  Brian T Fisher
Journal:  Curr Fungal Infect Rep       Date:  2013-03-01

2.  A review of clinical experience with newer antifungals in children.

Authors:  Renee M Fallon; Jennifer E Girotto
Journal:  J Pediatr Pharmacol Ther       Date:  2008-07

3.  Real-time PCR coupled with automated DNA extraction and detection of galactomannan antigen in serum by enzyme-linked immunosorbent assay for diagnosis of invasive aspergillosis.

Authors:  Catherine Costa; Jean-Marc Costa; Christophe Desterke; Françoise Botterel; Catherine Cordonnier; Stéphane Bretagne
Journal:  J Clin Microbiol       Date:  2002-06       Impact factor: 5.948

4.  In vitro release by Aspergillus fumigatus of galactofuranose antigens, 1,3-beta-D-glucan, and DNA, surrogate markers used for diagnosis of invasive aspergillosis.

Authors:  Monique A S H Mennink-Kersten; Dorien Ruegebrink; Nazhat Wasei; Willem J G Melchers; Paul E Verweij
Journal:  J Clin Microbiol       Date:  2006-05       Impact factor: 5.948

5.  Improved detection of circulating Aspergillus antigen by use of a modified pretreatment procedure.

Authors:  Monique A S H Mennink-Kersten; Dorien Ruegebrink; Rocus R Klont; Adilia Warris; Nicole M A Blijlevens; J Peter Donnelly; Paul E Verweij
Journal:  J Clin Microbiol       Date:  2008-02-20       Impact factor: 5.948

6.  Pulmonary aspergillosis in a patient with chronic granulomatous disease: confirmation by polymerase chain reaction and serological tests, and successful treatment with voriconazole.

Authors:  H Sambatakou; M Guiver; D Denning
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-10-18       Impact factor: 3.267

7.  Galactomannan antigenemia in pediatric oncology patients with invasive aspergillosis.

Authors:  Randall Hayden; Stanley Pounds; Katherine Knapp; Ruta Petraitiene; Robert L Schaufele; Tin Sein; Thomas J Walsh
Journal:  Pediatr Infect Dis J       Date:  2008-09       Impact factor: 2.129

8.  Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.

Authors:  Thomas F Patterson; George R Thompson; David W Denning; Jay A Fishman; Susan Hadley; Raoul Herbrecht; Dimitrios P Kontoyiannis; Kieren A Marr; Vicki A Morrison; M Hong Nguyen; Brahm H Segal; William J Steinbach; David A Stevens; Thomas J Walsh; John R Wingard; Jo-Anne H Young; John E Bennett
Journal:  Clin Infect Dis       Date:  2016-06-29       Impact factor: 9.079

Review 9.  Fungal infections in primary immunodeficiencies.

Authors:  Charalampos Antachopoulos; Thomas J Walsh; Emmanuel Roilides
Journal:  Eur J Pediatr       Date:  2007-06-06       Impact factor: 3.183

Review 10.  Current status of fungal cell wall components in the immunodiagnostics of invasive fungal infections in humans: galactomannan, mannan and (1-->3)-beta-D-glucan antigens.

Authors:  A Kedzierska; P Kochan; A Pietrzyk; J Kedzierska
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-11       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.